Effect of Cetuximab and EGFR Small Interfering RNA Combination Treatment in NSCLC Cell Lines with Wild Type EGFR and Use of KRAS as a Possible Biomarker for Treatment Responsiveness

BACKGROUND: The epidermal growth factor receptor (EGFR) is a therapeutic target for patients with non-small cell lung cancer (NSCLC). Cetuximab is an anti-EGFR monoclonal antibody that inhibits EGFR signaling and proliferation of colorectal cancer and head and neck cancers. Since only few NSCLC pati...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Yonago Acta Med
Hlavní autoři: Miyake, Naomi, Chikumi, Hiroki, Yamaguchi, Kosuke, Takata, Miyako, Takata, Miki, Okada, Kensaku, Kitaura, Tsuyoshi, Nakamoto, Masaki, Yamasaki, Akira
Médium: Artigo
Jazyk:Inglês
Vydáno: Tottori University Faculty of Medicine 2019
Témata:
Original Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6437414/
https://ncbi.nlm.nih.gov/pubmed/30962749
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky